Archive for the ‘DNA’ category: Page 15
Dec 15, 2017
Bioquark Inc. — Ira Pastor — Life After Death Society Podcast
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, cosmology, cryonics, disruptive technology, DNA, futurism, genetics, health
Dec 15, 2017
Bioquark Inc. — Turning Back Time — Back Room Stewdios Podcast
Posted by Ira S. Pastor in categories: aging, biological, biotech/medical, business, cryonics, DNA, futurism, genetics, health, life extension
Dec 15, 2017
Bioquark Inc. — School for Startups Radio
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, biotech/medical, business, cryonics, DNA, finance, genetics, health
Dec 15, 2017
Bioquark Inc. — CEO in 10 Podcast
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, biotech/medical, business, cryonics, DNA, finance, futurism, genetics
Dec 15, 2017
Bioquark Inc. — Health Secrets Made Simple Podcast
Posted by Ira S. Pastor in categories: aging, biological, biotech/medical, cryonics, DNA, genetics, health, life extension, science, transhumanism
Dec 15, 2017
Bioquark Inc. — Health Professional Radio
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, business, cryonics, DNA, genetics, health, life extension, science, transhumanism
Dec 15, 2017
Bioquark Inc. — The Inner Game Of Aging Podcast
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, cryonics, DNA, genetics, health, life extension, science, transhumanism
Jun 29, 2017
Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Posted by Ira S. Pastor in categories: aging, bioengineering, biotech/medical, disruptive technology, DNA, genetics, health, life extension, posthumanism, science
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
Feb 22, 2017
Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control
Posted by Ira S. Pastor in categories: bioengineering, biotech/medical, business, disruptive technology, DNA, genetics, health, science, sex
Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.
“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”
